Lv3
222 积分 2023-08-25 加入
Inflammation, proteases and cancer
5天前
已完结
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
5天前
已完结
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
11天前
已完结
Masking T cell engagers mitigates on-target off-tumor activity
20天前
已完结
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
23天前
已完结
BTK inhibitors: past, present, and future
26天前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
27天前
已完结
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
28天前
已完结
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
28天前
已完结
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
30天前
已完结
皖公网安备34019202002308
